Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05262673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05262673 · ClinicalTrials.gov record · last posted 2026-08-24

NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL

StatusTerminated
PhasePhase 1
Started2026-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effector cytotoxic T lymphocytes (CTLs) and immune-modified dendritic cell vaccine (DCvac). This approach is aimed to achieve NGS MRD negative in B-ALL patients, which can identify a very low risk of relapse and define patients with possible long-term remission without further treatment.

Protocol amendment history 3 changes detected by DataLookout

2026-08-25
Trial terminated
2026-08-25
Primary completion moved earlier: 2029-12-31 → 2026-07-01
2026-08-25
Completion moved earlier: 2030-12-31 → 2026-07-31
Trial Details
NCT Number NCT05262673
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions B-Cell Acute Lymphoblastic Leukemia
Enrollment 10 participants
Start Date 2026-06-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-24